Scarica l'app Stockscreener
4.9144
0.21%
-0.0544
Cellectar Biosciences Inc Borsa (CLRB) Ultime notizie
Cellectar Biosciences announces one-for-thirty reverse stock split - MarketScreener
Cellectar Biosciences (CLRB) Announces One-for-Thirty Reverse St - GuruFocus
Cellectar Biosciences announces 1:30 reverse stock split - Investing.com
Cellectar Biosciences (CLRB) Announces Reverse Stock Split | CLR - GuruFocus
Cellectar Biosciences Reports 1-for-30 Reverse Stock Split, Effective June 24 - marketscreener.com
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split | CLRB Stock News - GuruFocus
Cellectar Biosciences, Inc. Announces One-for-Thirty Reverse Stock Split Effective June 24, 2025 - Nasdaq
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split - GlobeNewswire
Roth Capital Issues Positive Estimate for CLRB Earnings - Defense World
Cellectar Biosciences Approves Reverse Stock Split Proposal - TipRanks
Cellectar Biosciences (CLRB) Reports Promising Phase 1 Trial Res - GuruFocus
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 - GlobeNewswire
Cellectar reports improved survival in pediatric brain tumor trial By Investing.com - Investing.com India
Cellectar reports improved survival in pediatric brain tumor trial - Investing.com
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma - The Manila Times
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma | CLRB Stock News - GuruFocus
Breakthrough: New Drug Doubles Survival Time in Aggressive Childhood Brain Cancer Trial - Stock Titan
Squarepoint Ops LLC Makes New Investment in Cellectar Biosciences, Inc. (NASDAQ:CLRB) - Defense World
Cellectar Biosciences announces $2.5 million stock sale By Investing.com - Investing.com India
Cellectar Biosciences Enters into Common Stock Agreements to Rai - GuruFocus
Cellectar Biosciences Expects to Raise $2.5 Million via Stock Sale, Warrant Exercise - marketscreener.com
Cellectar Biosciences (CLRB) Secures $2.5 Million from Stock Sal - GuruFocus
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? - Yahoo Finance
Cellectar Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Cellectar Biosciences (CLRB) Secures $2.5M Through Stock Sale Agreements | CLRB Stock News - GuruFocus
Cellectar Biosciences announces $2.5 million stock sale - Investing.com Australia
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules | CLRB Stock News - GuruFocus
Cellectar Biosciences Enters into Common Stock Agreements - GlobeNewswire
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules - Yahoo Finance
FDA Designation Sparks Rally For This Biotech - The Globe and Mail
Cellectar Biosciences stock soars on FDA breakthrough designation - Investing.com Australia
Cellectar Biosciences stock soars on FDA breakthrough designation By Investing.com - Investing.com Canada
Cellectar Biosciences Stock Price, Quotes and Forecasts | NASDAQ:CLRB - Benzinga
Cellectar Biosciences (CLRB) Secures Breakthrough Therapy Designation | CLRB Stock News - GuruFocus
What's Behind Cellectar Biosciences' Stock Surge? FDA Update Explained - Yahoo Finance
US Stocks Higher; Dollar Tree Shares Plunge After Q1 Earnings - Benzinga
Cellectar Granted U.S. FDA Breakthrough Therapy Designation - GlobeNewswire
Cellectar Biosciences Says FDA Granted Breakthrough Therapy Designation for Experimental Cancer Drug; Shares Rise Pre-Bell - marketscreener.com
Cellectar Biosciences (CLRB) Gains FDA Breakthrough Therapy Desi - GuruFocus
Cellectar Biosciences Announces Breakthrough Therapy Designation for iopofosine I 131, Reports 83.6% Overall Response Rate from CLOVER WaM Phase 2 Study - Nasdaq
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM) - Quantisnow
Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies - Yahoo Finance
CVM Stock Offering Priced Below Previous Closing Value | CVM Stock News - GuruFocus
Cellectar Biosciences (NASDAQ:CLRB) Now Covered by StockNews.com - Defense World
Cellectar signals Q3 EMA decision for conditional iopofosine approval while advancing pipeline and exploring strategic alternatives - MSN
Analysts Update Their Estimates For Cellectar Biosciences Inc - Stocksregister
Cellectar Biosciences’ (CLRB) “Hold” Rating Reiterated at Maxim Group - Defense World
Roth Capital Brokers Increase Earnings Estimates for CLRB - Defense World
Cellectar Biosciences Earnings Call: Progress Amid Challenges - TipRanks
Cellectar Biosciences (CLRB) Downgraded to 'Hold' by Maxim Group - GuruFocus
StockNews.com Initiates Coverage on Cellectar Biosciences (NASDAQ:CLRB) - Defense World
Cellectar Biosciences (CLRB) Downgraded Amid Strategic Uncertain - GuruFocus
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2025 Earnings Call Transcript - Insider Monkey
1.93%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):